Seelos Therapeutics Past Earnings Performance
Past criteria checks 0/6
Seelos Therapeutics's earnings have been declining at an average annual rate of -27.9%, while the Pharmaceuticals industry saw earnings growing at 14% annually. Revenues have been growing at an average rate of 55.6% per year.
Key information
-27.9%
Earnings growth rate
43.4%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | 55.6% |
| Return on equity | n/a |
| Net Margin | -3,295.9% |
| Last Earnings Update | 30 Sep 2023 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses BreakdownBeta
How Seelos Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 23 | 2 | -51 | 13 | 40 |
| 30 Jun 23 | 1 | -81 | 12 | 59 |
| 31 Mar 23 | 1 | -73 | 12 | 59 |
| 31 Dec 22 | 0 | -74 | 12 | 59 |
| 30 Sep 22 | 0 | -82 | 17 | 63 |
| 30 Jun 22 | 0 | -73 | 17 | 28 |
| 31 Mar 22 | 0 | -61 | 17 | 33 |
| 31 Dec 21 | 0 | -66 | 15 | 47 |
| 30 Sep 21 | 0 | -45 | 9 | 38 |
| 30 Jun 21 | 0 | -39 | 9 | 29 |
| 31 Mar 21 | 0 | -33 | 8 | 21 |
| 31 Dec 20 | 0 | -19 | 8 | 11 |
| 30 Sep 20 | 0 | -23 | 7 | 0 |
| 30 Jun 20 | 0 | -22 | 6 | -8 |
| 31 Mar 20 | 0 | -21 | 6 | -3 |
| 31 Dec 19 | 0 | -51 | 6 | 0 |
| 30 Sep 19 | 0 | -42 | 5 | 0 |
| 30 Jun 19 | 0 | -40 | 5 | 9 |
| 31 Mar 19 | 0 | -38 | 4 | 7 |
| 31 Dec 18 | 0 | -3 | 3 | 1 |
| 30 Sep 18 | 0 | -3 | 2 | 1 |
| 30 Jun 18 | 0 | -2 | 1 | 1 |
| 31 Mar 18 | 0 | -2 | 1 | 1 |
| 31 Dec 17 | 0 | -12 | 7 | 3 |
Quality Earnings: NXE is currently unprofitable.
Growing Profit Margin: NXE is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: NXE is unprofitable, and losses have increased over the past 5 years at a rate of 27.9% per year.
Accelerating Growth: Unable to compare NXE's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NXE is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (3.9%).
Return on Equity
High ROE: NXE's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.